{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:32:45Z","timestamp":1777923165047,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"\n Introduction:<\/jats:title>\n Rapid increase in antimicrobial-resistance is leading to urgent need for newer broad-spectrum antimicrobials. Therefore, we have evaluated the antimicrobial r\u00e9sistance spectrum of India-discovered novel antibiotics (levonadifloxacin) against clinical isolates recovered from cancer patients.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n The study was conducted in the microbiology department, over a period of 1 year between May 2021 and June 2022 and 374 consecutive and nonduplicate Gram-positive (GPC) and MDR Gram Negative Bacteria (GNB) isolate were analyzed from 3,880 cancer patients in study. The identification and antimicrobial sensitivities of bacterial isolates were performed according to standard laboratory protocols by using automated identification system (VITEK-2-8.01; BioM\u00e9rieux, Germany). The activity of levonadifloxacin and comparator antibiotics was evaluated using disk diffusion methods as per Clinical and Laboratory Standards Institute 2022 guidelines.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The mean age of the patients were 51.6\u2009\u00b1\u200914.59 years with male: female ratio of 1.2:1. The prevalence of GPC was 167 (44.65%) and MDR-GNB was 207 (55.34%). The most common GPC was\n Staphylococcus aureus<\/jats:italic>\n ; 97 (58.08%) followed by\n Enterococcus species<\/jats:italic>\n 66 (39.52%). In GNB,\n Escherichia coli<\/jats:italic>\n ; 93 (44.92%) was the most common followed by\n Klebsiella pneumoniae<\/jats:italic>\n ; 45 (21.73%). Levonadifloxacin susceptibility was present in 98.7% methicillin-resistant\n S. aureus<\/jats:italic>\n and 96% methicillin-susceptible\n S. aureus<\/jats:italic>\n and 77.1%\n Enterococcus-<\/jats:italic>\n species. Additionally, all the fluoroquinolones-resistant\n S. aureus<\/jats:italic>\n isolates were susceptible to levonadifloxacin (WCK-771) except one isolate. Also, levonadifloxacin-(WCK-771) exhibits 100% susceptibility fluoroquinolone susceptible GNB, such as\n E. coli<\/jats:italic>\n ,\n K. pneumoniae, Pseudomonas species<\/jats:italic>\n , and\n Acinetobacter species<\/jats:italic>\n . Interestingly, all fluoroquinolones-resistant\n Salmonella species<\/jats:italic>\n and\n Stenotrophomonas maltophilla<\/jats:italic>\n exhibited 100% susceptibility to levonadifloxacin (WCK-771).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n Levonadifloxacin (WCK-771) possesses potent activity against all the MDR Gram-positive pathogens including the coverage of susceptible\n Enterobacterales<\/jats:italic>\n and MDR\n S. maltophilla<\/jats:italic>\n and\n Burkholderia cepacia<\/jats:italic>\n suggesting its potential utility in the management of polymicrobial infections.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/mdr.2022.0313","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T17:37:15Z","timestamp":1707845835000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["In Vitro<\/i>\n Assessment of Antimicrobial Activity of Novel Fluoroquinolone, Levonadifloxacin (WCK 771) Against Multi-Drug-Resistant Clinical Isolates from Cancer Patients in India"],"prefix":"10.1177","volume":"30","author":[{"given":"Vijeta","family":"Bajpai","sequence":"first","affiliation":[{"name":"Department of Microbiology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Critical Care, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwita","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"sure","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Sarode","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujit","family":"Bharti","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of DMG Urooncology, Department of Surgical Oncology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Homi Bhabha Cancer Centre\/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7090277"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.200647"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25061340"},{"key":"e_1_3_4_5_2","unstructured":"Siddiqui AH Koirala J. Methicillin Resistant S. aureus. In: StatPearls. StatPearls Publishing: Treasure Island FL; 2022."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8020191"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-020-05163-6"},{"issue":"8","key":"e_1_3_4_8_2","first-page":"2156","article-title":"Levonadifloxacin, a recently approved benzoquinolizin fluoroquinolone, exhibits potent in vitro activity against contemporary S. aureusisolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital","volume":"75","author":"Bakthavatchalam YD","year":"2020","unstructured":"Bakthavatchalam YD, , Shankar A, , Muniyasamy R, et al. Levonadifloxacin, a recently approved benzoquinolizin fluoroquinolone, exhibits potent in vitro activity against contemporary S. aureusisolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. J Antimicrob Chemother, 2020; 75(8):2156\u20132159.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.23958\/ijirms\/vol06-i12\/1295"},{"key":"e_1_3_4_10_2","unstructured":"Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute. CLSI Document M100 32th ed. CLSI: Wayne PA; 2022."},{"key":"e_1_3_4_11_2","unstructured":"Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute. CLSI Document M100 26th ed. CLSI: Wayne PA; 2016."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz493"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_20_307"},{"key":"e_1_3_4_14_2","unstructured":"Flamm RK Farrell DJ Sader HS et al. In Vitro Activity of WCK 771 a Benzoquinolizine Fluoroquinolone (Levonadifloxacin (WCK 771)) When Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance proGram Poster Sunday-456. ASM Microbe: Boston MA; 2016."},{"issue":"7","key":"e_1_3_4_15_2","first-page":"DC26","article-title":"Levonadifloxacin: A novel approved drug exhibiting potent in vitro activity against Gram positive bacterial isolates from patients admitted in intensive care units","volume":"15","author":"Tasneem S","year":"2021","unstructured":"Tasneem S, , Rafat S, , San Gram P, et al. Levonadifloxacin: A novel approved drug exhibiting potent in vitro activity against Gram positive bacterial isolates from patients admitted in intensive care units. J Clin Diagn Res, 2021; 15(7):DC26\u2013DC29.","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2021.1588"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S229882"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025320"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_4_20_2","article-title":"Emergence of carbapenem resistant non-fermenting gram-negative bacilli isolated in an ICU of a tertiary care hospital","author":"Agarwal S","year":"2017","unstructured":"Agarwal S, , Kakati B, , Khanduri S, et al. Emergence of carbapenem resistant non-fermenting gram-negative bacilli isolated in an ICU of a tertiary care hospital. J Clin Diagn Res, 2017;11(1).","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2020.1719701"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2022.0313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2022.0313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2022.0313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:40:52Z","timestamp":1777668052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2022.0313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"alternative-id":["10.1089\/mdr.2022.0313"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2022.0313","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}